Procter & Gamble Hygiene and Health Care has confirmed the appointment of Ms. Srividya Srinivasan as Whole-time Director, effective July 1, 2026. The appointment was approved by shareholders at the company's 62nd Annual General Meeting (AGM) held on September 8, 2026.

The board had previously proposed the five-year tenure for Ms. Srinivasan in May 2026, subject to shareholder ratification. The final approval solidifies the leadership transition, with Ms. Srinivasan assuming the role retroactively from the start of the financial year.

Voting Participation and Results

The record date for the AGM was September 1, 2026, with a total of 65,199 shareholders on record. Voting participation was driven primarily by promoter and institutional investors via remote e-voting.

Promoter group participation stood at 100%, casting all votes in favor of the resolutions. Institutional public shareholders also showed high engagement, with a 94.51% participation rate. Retail non-institutional shareholder participation was minimal at 0.42%.

Resolution Outcomes

All six resolutions were approved. The key outcomes included:

• Financial Statements: Adoption of the Audited Balance Sheet as at March 31, 2026, and Statement of Profit and Loss for FY26 passed with 99.997% votes in favor.
• Dividend: Confirmation of interim dividend and declaration of final dividend for FY26 received 99.997% support.
• Board Appointments: Re-appointment of Non-Executive Director Pramod Agarwal passed with 99.95% approval. Appointment of Srividya Srinivasan as Whole-time Director secured 99.10% support.
• Auditor Remuneration: Ratification of remuneration for the Cost Auditor for FY27 was approved with 99.997% votes in favor.
• Related Party Transaction: Approval of material related-party transaction for purchase of goods passed with 99.98% support from independent shareholders. Promoter group did not vote on this resolution as they were interested parties.

Governance Compliance

The scrutinizer report confirmed compliance with Section 108 of the Companies Act, 2013, and Rule 20 & 21 of the Companies (Management and Administration) Rules, 2014. Remote e-voting was facilitated by National Securities Depositories Limited (NSDL), with the voting window open from September 4 to September 7, 2026.

No invalid votes were recorded across any resolution. The combined report from remote e-voting and AGM-day electronic voting was unblocked and downloaded in the presence of two independent witnesses.

Procter & Gamble Hygiene and Health Care reported a net profit of ₹857 crore for the financial year ended March 31, 2026, an increase from ₹637 crore in the previous period. Revenue from operations rose to ₹4,290 crore, up from ₹3,374 crore in the prior year. The previous financial year (FY25) was a nine-month period due to the company’s shift in fiscal calendar, making direct year-on-year comparisons less precise.

The Board of Directors recommended a final dividend of ₹60 per equity share for FY26. This follows an interim dividend of ₹195 per share, which included a one-time special dividend of ₹25 per share, paid in February 2026. The aggregate dividend for the year amounts to ₹255 per share, subject to shareholder approval at the 62nd Annual General Meeting.

Financial Performance

The company’s profitability metrics showed significant improvement alongside top-line growth. Profit before tax stood at ₹1,167 crore, compared to ₹862 crore in the previous period. Earnings per share increased to ₹264 from ₹196 in the prior year.

What the Numbers Show

The improvement in net profit margin is notable. In FY26, the net profit margin expanded to approximately 20%, up from 19% in the previous nine-month period. This suggests that cost management or operational efficiencies may have contributed to bottom-line growth outpacing revenue growth. Additionally, the return on capital employed improved to 1.35 from 1.03, indicating better utilization of capital.

Operational Highlights

The company continued its focus on innovation across feminine care and healthcare portfolios. Key brands include Whisper and Vicks. The Whisper Period Panty portfolio and Vicks VapoRub were highlighted as strong performers. The company also launched Vicks Cough Syrup, targeting the herbal remedy segment, and upgraded Zzzquil Natura Sleep Gummies.

Corporate Governance

Several changes occurred in the board and management structure during the year. Mr. Gagan Sawhney stepped down as Non-Executive Director in October 2025. Ms. Mrinalini Srinivasan ceased to be Chief Financial Officer in June 2025, succeeded by Mr. Gaurav Bhartia. Post-closure of the financial year, Ms. Srividya Srinivasan was appointed as Whole-time Director and CFO effective July 1, 2026.

The 62nd Annual General Meeting will be held on September 8, 2026, via video conference. Shareholders will vote on the re-appointment of Mr. Pramod Agarwal and the appointment of Ms. Srividya Srinivasan.